


In re Application of: Levitzki et al
Serial No.: 10/715,547
Filed: November 19, 2003
Office Action Mailing Date: April 16, 2007

Examiner: Tamthom N. Truong
Group Art Unit: 1624
Attorney Docket: 27148


In the specification:

Please amend page 6, lines 10-14 ([paragraph 0013]) and page 19, lines 7-11 (paragraph [0065]) as follows:



(Compound I)

or



(Compound II)

Please amend page 6, line 2 (paragraph [0012]) as follows:

It is an object of the present invention to provided PDGF receptor kinase

In re Application of: Levitzki et al
Serial No.: 10/715,547
Filed: November 19, 2003
Office Action Mailing Date: April 16, 2007

Examiner: Tamthom N. Truong
Group Art Unit: 1624
Attorney Docket: 27148

Please amend page 7, lines 6-8 (paragraph [0017]) as follows:

consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl,
hydroxy, alkoxy, halo, C-carboxy, O-carboxy, carbonyl, thiocarbonyl, C-amido,
guanyl~~guanyl~~, sulfonyl, trihalomethane-sulfonyl and a pair of electrons,

Please amend page 17, line 10 (paragraph [0061]) as follows:

not limited to, PDGFR, EGFR, IGFR, and FGFR. More specifically, the

Please amend page 20, lines 2 and 3 (paragraph [0069]) as follows:

alkynyl, cycloalkyl, aryl, hydroxy, alkoxy, halo, C-carboxy, O-carboxy,
carbonyl, thiocarbonyl, C-amido, guanyl~~guanyl~~, sulfonyl, trihalomethane-sulfonyl and